Table of Contents Author Guidelines Submit a Manuscript
Case Reports in Oncological Medicine
Volume 2016, Article ID 3161768, 6 pages
http://dx.doi.org/10.1155/2016/3161768
Case Report

Systemic Mastocytosis with Smoldering Multiple Myeloma: Report of a Case

1Department of Medicine, Staten Island University Hospital, Northwell Health, 475 Seaview Avenue, Staten Island, NY 10305, USA
2Department of Hematology/Oncology, Staten Island University Hospital, Northwell Health, 475 Seaview Avenue, Staten Island, NY 10305, USA
3Department of Pathology, Staten Island University Hospital, Northwell Health, 475 Seaview Avenue, Staten Island, NY 10305, USA

Received 10 March 2016; Accepted 4 May 2016

Academic Editor: Junya Kuroda

Copyright © 2016 Sassine Ghanem et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. P. Valent, H.-P. Horny, L. Escribano et al., “Diagnostic criteria and classification of mastocytosis: a consensus proposal,” Leukemia Research, vol. 25, no. 7, pp. 603–625, 2001. View at Publisher · View at Google Scholar · View at Scopus
  2. H. P. Horny, J. M. Bennett, B. J. Bain et al., “Mastocytosis,” in WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues, S. H. Swerdlow, S. H. Camp, E. Harris et al., Eds., pp. 54–63, International Agency for Research on Cancer, Lyon, France, 4th edition, 2008. View at Google Scholar
  3. W. D. Travis, C.-Y. Li, L. T. Yam, E. J. Bergstralh, and R. G. Swee, “Significance of systemic mast cell disease with associated hematologic disorders,” Cancer, vol. 62, no. 5, pp. 965–972, 1988. View at Publisher · View at Google Scholar · View at Scopus
  4. K. Sotlar, W. Saeger, F. Stellmacher et al., “‘Occult’ mastocytosis with activating c-kit point mutation evolving into systemic mastocytosis associated with plasma cell myeloma and secondary amyloidosis,” Journal of Clinical Pathology, vol. 59, no. 8, pp. 875–878, 2006. View at Publisher · View at Google Scholar · View at Scopus
  5. S. Du, H. H. Rashidi, D. T. Le et al., “Systemic mastocytosis in association with chronic lymphocytic leukemia and plasma cell myeloma,” International Journal of Clinical and Experimental Pathology, vol. 3, no. 4, pp. 448–457, 2010. View at Google Scholar
  6. P. Jain, S. Verstovsek, R. Z. Orlowski, E. Yap, and H. M. Amin, “An unusual case of aggressive systemic mastocytosis with associated refractory plasma cell myeloma,” Clinical Lymphoma, Myeloma and Leukemia, vol. 12, no. 6, pp. 459–462, 2012. View at Publisher · View at Google Scholar · View at Scopus
  7. K. Filanovsky, S. Lev, M. Haran et al., “Systemic mastocytosis associated with smoldering multiple myeloma: an unexpected diagnosis in a patient with a rash,” Leukemia & Lymphoma, vol. 51, no. 6, pp. 1152–1154, 2010. View at Publisher · View at Google Scholar · View at Scopus
  8. P. Motwani, M. Kocoglu, and R. B. Lorsbach, “Systemic mastocytosis in association with plasma cell dyscrasias: report of a case and review of the literature,” Leukemia Research, vol. 33, no. 6, pp. 856–859, 2009. View at Publisher · View at Google Scholar · View at Scopus
  9. F. Stellmacher, K. Sotlar, L. Balleisen, P. Valent, and H.-P. Horny, “Bone marrow mastocytosis associated with IgM kappa plasma cell myeloma,” Leukemia and Lymphoma, vol. 45, no. 4, pp. 801–805, 2004. View at Publisher · View at Google Scholar · View at Scopus
  10. W. Hagen, J. Schwarzmeier, S. Walchshofer et al., “A case of bone marrow mastocytosis associated with multiple myeloma,” Annals of Hematology, vol. 76, no. 3-4, pp. 167–174, 1998. View at Publisher · View at Google Scholar · View at Scopus
  11. S. T. Pullarkat, F. Sedarat, R. Paquette, and J. Said, “Systemic mastocytosis with plasma cell dyscrasia: report of a case,” Leukemia Research, vol. 32, no. 7, pp. 1160–1163, 2008. View at Publisher · View at Google Scholar · View at Scopus
  12. A. Pardanani, K.-H. Lim, T. L. Lasho et al., “Prognostically relevant breakdown of 123 patients with systemic mastocytosis associated with other myeloid malignancies,” Blood, vol. 114, no. 18, pp. 3769–3772, 2009. View at Publisher · View at Google Scholar · View at Scopus
  13. O. Tournilhac, D. D. Santos, L. Xu et al., “Mast cells in Waldenstrom's macroglobulinemia support lymphoplasmacytic cell growth through CD154/CD40 signaling,” Annals of Oncology, vol. 17, no. 8, pp. 1275–1282, 2006. View at Publisher · View at Google Scholar · View at Scopus
  14. D. Molin, M. Fischer, Z. Xiang et al., “Mast cells express functional CD30 ligand and are the predominant CD30L-positive cells in Hodgkin's disease,” British Journal of Haematology, vol. 114, no. 3, pp. 616–623, 2001. View at Publisher · View at Google Scholar · View at Scopus
  15. R. Bataille, M. Jourdan, X.-G. Zhang, and B. Klein, “Serum levels of interleukin 6, a potent myeloma cell growth factor, as a reflect of disease severity in plasma cell dyscrasias,” Journal of Clinical Investigation, vol. 84, no. 6, pp. 2008–2011, 1989. View at Publisher · View at Google Scholar · View at Scopus
  16. R. M. Lemoli, A. Fortuna, A. Grande et al., “Expression and functional role of c-kit ligand (SCF) in human multiple myeloma cells,” British Journal of Haematology, vol. 88, no. 4, pp. 760–769, 1994. View at Publisher · View at Google Scholar · View at Scopus
  17. T. C. Theoharides, K.-D. Alysandratos, A. Angelidou et al., “Mast cells and inflammation,” Biochimica et Biophysica Acta (BBA)—Molecular Basis of Disease, vol. 1822, no. 1, pp. 21–33, 2012. View at Publisher · View at Google Scholar · View at Scopus
  18. H.-P. Horny, K. Sotlar, F. Stellmacher, P. Valent, and J. Grabbe, “An unusual case of systemic mastocytosis associated with chronic lymphocytic leukaemia (SM-CLL),” Journal of Clinical Pathology, vol. 59, no. 3, pp. 264–268, 2006. View at Publisher · View at Google Scholar · View at Scopus
  19. Y. Kim, L. M. Weiss, Y.-Y. Chen, and V. Pullarkat, “Distinct clonal origins of systemic mastocytosis and associated B-cell lymphoma,” Leukemia Research, vol. 31, no. 12, pp. 1749–1754, 2007. View at Publisher · View at Google Scholar · View at Scopus
  20. V. Pullarkat, V. Bedell, Y. Kim et al., “Neoplastic mast cells in systemic mastocytosis associated with t(8;21) acute myeloid leukemia are derived from the leukemic clone,” Leukemia Research, vol. 31, no. 2, pp. 261–265, 2007. View at Publisher · View at Google Scholar · View at Scopus
  21. W. R. Sperr, J. Drach, A. W. Hauswirth et al., “Myelomastocytic leukemia: evidence for the origin of mast cells from the leukemic clone and eradication by allogeneic stem cell transplantation,” Clinical Cancer Research, vol. 11, no. 19 I, pp. 6787–6792, 2005. View at Publisher · View at Google Scholar · View at Scopus
  22. P. Valent, C. Akin, W. R. Sperr et al., “Mastocytosis: pathology, genetics, and current options for therapy,” Leukemia and Lymphoma, vol. 46, no. 1, pp. 35–48, 2005. View at Publisher · View at Google Scholar · View at Scopus
  23. W. R. Sperr and P. Valent, “Diagnosis, progression patterns and prognostication in mastocytosis,” Expert Review of Hematology, vol. 5, no. 3, pp. 261–274, 2012. View at Publisher · View at Google Scholar · View at Scopus
  24. M. Arock and P. Valent, “Pathogenesis, classification and treatment of mastocytosis: state of the art in 2010 and future perspectives,” Expert Review of Hematology, vol. 3, no. 4, pp. 497–516, 2010. View at Publisher · View at Google Scholar · View at Scopus
  25. K.-H. Lim, A. Tefferi, T. L. Lasho et al., “Systemic mastocytosis in 342 consecutive adults: survival studies and prognostic factors,” Blood, vol. 113, no. 23, pp. 5727–5736, 2009. View at Publisher · View at Google Scholar · View at Scopus
  26. A. Pardanani, “How I treat patients with indolent and smoldering mastocytosis (rare conditions but difficult to manage),” Blood, vol. 121, no. 16, pp. 3085–3094, 2013. View at Publisher · View at Google Scholar · View at Scopus
  27. J. H. Butterfield and C. R. Weiler, “Systemic mastocytosis in the elderly,” American Journal of Hematology, vol. 88, no. 5, pp. 406–408, 2013. View at Publisher · View at Google Scholar · View at Scopus
  28. K. H. Lim, A. Pardanani, J. H. Butterfield, C.-Y. Li, and A. Tefferi, “Cytoreductive therapy in 108 adults with systemic mastocytosis: outcome analysis and response prediction during treatment with interferon-alpha, hydroxyurea, imatinib mesylate or 2-chlorodeoxyadenosine,” American Journal of Hematology, vol. 84, no. 12, pp. 790–794, 2009. View at Publisher · View at Google Scholar · View at Scopus
  29. A. Vega-Ruiz, J. E. Cortes, M. Sever et al., “Phase II study of imatinib mesylate as therapy for patients with systemic mastocytosis,” Leukemia Research, vol. 33, no. 11, pp. 1481–1484, 2009. View at Publisher · View at Google Scholar · View at Scopus
  30. J. Gotlib, H. C. Kluin-Nelemans, T. I. George et al., “Demonstrates a high rate of durable responses in patients with advanced systemic mastocytosis: results from the fully accrued global phase 2 CPKC412D2201 trial,” in Proceedings of the 56th Annual Meeting of the American Society of Hematology, vol. 124, no. 21, p. 636, San Francisco, Calif, USA, December 2014.